Experts discuss the future of modular manufacturing and the challenges that biopharma manufacturers face in facility design
Program review can help quality risk management live up to the promise of ICH Q9.
Careful selection of downstream processing conditions is a must.
Chinese healthcare reforms may be a double-edged sword for foreign companies.
Design space generation is encouraged in new product development.
Developing and maintaining a current master plan for cleaning in multi-product facilities are crucial.
Part II of this three-part series presents a roadmap to human error prevention.
Going beyond pharmacopeial requirements is essential for the quality and safety of raw materials.
Single-use products offer options and choices for biopharma mixing.